The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Pirtobrutinib enhances T-cell anti-tumor immunity in CLL
In this interview, Alexey Danilov, MD, PhD, City of Hope, Duarte, CA, discusses the findings of a preclinical study that evaluated the effect of pirtobrutinib, a non-covalent BTK inhibitor, on T-cell immunity in chronic lymphocytic leukemia (CLL). This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
